Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 11/2018

01-11-2018 | Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)

Wireless 24, 48, and 96 Hour or Impedance or Oropharyngeal Prolonged pH Monitoring: Which Test, When, and Why for GERD?

Authors: Soojong Chae, Joel E. Richter

Published in: Current Gastroenterology Reports | Issue 11/2018

Login to get access

Abstract

Purpose of Review

pH monitoring technologies are routinely utilized in practice to further evaluate symptoms of gastro-esophageal reflux disease and laryngopharyngeal reflux (LPR). This is a review of the recent literature of the available pH monitoring technology and creates an algorithm in the diagnostic work up of a patient with GERD or LPR.

Recent Findings

The catheter-free wireless pH monitor traditionally collects data for 48 h. Recent studies have found that extending to 96 h can be helpful in patients with conflicting results on the first 2 days of the study. In addition, 96 h can allow for testing both on and off of PPI therapy. The oropharyngeal monitoring device is a newer technology that is designed to aid in the diagnoses of LPR. There are limitations with this technology as there is no universal abnormal cutoff and some studies have suggested a poor correlation between multichannel intraluminal impedance-pH (MII-pH) and the oropharyngeal monitoring device. MII-pH has recently developed two additional parameters, the measurement of three 10-min nighttime periods and the post-reflux swallow-induced peristaltic wave (PSPW) index, both of which may increase accuracy of testing.

Summary

Each of these technologies can provide unique data regarding acid reflux exposure in the esophagus and oropharynx. The wireless pH monitor performed off of PPI therapy can help to establish or exclude the diagnosis of GERD. For those patients with refractory symptoms on PPI, MII-pH study can be performed while on therapy and provides data regarding the response to treatment. Oropharyngeal pH monitoring is being utilized in some practices to aid in diagnosis of LPR, but the scientific validity is controversial.
Literature
1.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.CrossRef
2.
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-esophageal reflux disease: a system review. Gut. 2014;63:871–80.CrossRef
3.
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.CrossRef
4.
Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory pH monitoring using a wireless system. Am J Gastroenterol. 2003;98:740–9.CrossRef
5.
• Richter JE, Pandolfino JE, Vela MF, et al. Utilization of wireless pH monitoring technology: A summary of the proceedings of the Esophageal Diagnostic Working Group. Dis Esophagus. 2013;26:755–65 An evidence-based summary of the wireless pH monitoring capsule and provides an algorithm for patients with GERD not responding to medical therapy. CrossRef
6.
Hirano I, Zhang Q, Pandolfino JE, Kahrias PJ. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2005;3:1083–5.CrossRef
7.
Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluation gastroesophageal reflux disease. Clin Gastroetnerol Hepatol. 2005;3:329–34.CrossRef
8.
Scarpulla G, Camilleri S, Galante P, Manganaro M, Fox M. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4-day wireless pH studies. Am J Gastroenterol. 2007;102(12):2642–7.CrossRef
9.
• Patel R, Chae S, Kumar A, Richter JE. Sedation and afternoon placement of the 48-hr wireless ambulatory capsule results in more reflux on the first day. J Clinical Gastroenterol. 2017;51(7):594–8 In 225 patients, morning versus afternoon placement of wireless motility capsule were compared. The median DeMeester score was 15.3 for morning placement and 24.7 for afternoon placement. CrossRef
10.
Patel R, Chae S, Jacobs J, Kumar A, Richter J. 96-hour esophageal pH monitoring: the tiebreaker for abnormal DeMeester score and symptom index. Gastroenterology. 2018;154(6):S-487–7.
11.
Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48- hour periods off and on PPI therapy. Am J Gastroenterol. 2008;103:1631–7.CrossRef
12.
Chang B, MacNeil SD, Morrison MD, Lee PK. The reliability of the reflux finding score among general otolaryngologists. J Voice. 2015;29:572–7.CrossRef
13.
Chiou E, Rosen R, Jiang H, Nurko S. Diagnosis of supra-esophageal gastric reflux: correlation of oropharyngeal pH with esophageal impedance monitoring for gastro-esophageal reflux. Neurogastroenterol Motil. 2011;23:717–e326.CrossRef
14.
Ummarion D, Vandermeulen L, Roosens B, et al. Gastroesophageal reflux evaluation in patients affected by chronic cough: Restech versus multichannel intraluminal impedance/pH Metry. Laryngoscope. 2013;123:980–4.CrossRef
15.
Yuksel ES, Slaughter JC, Muktar N, Ochieng M, et al. An oropharyngeal pH monitoring device to evaluate patients with chronic laryngitis. Neurogastroenterol Motil. 2013;25:e-315–e323.CrossRef
16.
Wiener GJ, Tsukashima R, Kelly C, Wolf E, Schmeltzer M, Bankert C, et al. Oropharyngeal pH monitoring for the detection of liquid and aerosolized supraesophageal gastric reflux. J Voice. 2009;23:498–504.
17.
• Yadlapati R, Pandolfino JE, Lidder AK, Shabeeb N, et al. Oropharyngeal pH testing does not predict response to proton pump inhibitor therapy in patients with laryngeal symptoms. Am J Gastroenterol. 2016;111:1517–24 34 patients underwent video laryngoscopy and 24 h oropharyngeal pH monitoring followed by an 8- to 12-week trial of omeprazole 40 mg daily. Oropharyngeal acid exposure was no different between those who responded to PPI therapy, no response to PPI, and partial response to PPI. In secondary analysis, there was an inverse relation between PPI response and oropharyngeal acid exposure. CrossRef
18.
Silny J. Intraluminal multiple electrical impedance procedures for measurement of gastrointestinal motility. Neurogastroenterol Motil. 1991;3:151–62.CrossRef
19.
Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in GERD. Aliment Pharmacol Ther. 2010;32:334–43.CrossRef
20.
Hilal A, Agrawal A, Castell DO. Combined multi-channel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol. 2007;5:172–7.CrossRef
21.
Hemmerink GJM, Bedenoord AJ, Wiresten BLAM, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: “on” or “off” proton pump inhibitors. Am J Gastroenterol. 2008;103:2446–53.CrossRef
22.
•• Zerbid F, Roman S, Bruley Des Varannes S, et al. Normal values of pharyngeal and esophageal 24 hour impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol Hepatol. 2013;11:366–72 Basis for normal values on and off PPIs from 46 healthy controls. Analysis of esophageal events were reproducible, but analyses of pharyngeal events was not. CrossRef
23.
Zerbid F, Romn S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006;101:1956–63.CrossRef
24.
Hemmink GJ, Bredenoord AJ, Aanen MC, et al. Computer analysis of 24 hour esophageal impedance signals. Scand J Gastroenterol. 2011;46:271–6.CrossRef
25.
• Koop A, Francis DL, DeVault KR. Visual and automated computer analysis differ substantially in detection of acidic reflux in MII-pH monitoring. Clin Gastro Hepatol. 2018;16:979–80 The visual and automated computer analysis of 33 M11-pH studies agreed in only 78% of pH drops to < pH4. CrossRef
26.
Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicenter study using combined ambulatory impedance – pH monitoring. Gut. 2006;55:1398–402.CrossRef
27.
Kline MM, Ewing M, Simpson N et al. The utility of intraluminal impedance in patients with gastroesophageal reflux disease-like symptoms but normal endoscopy and 24 hour pH testing, Clin Gastroenterology Hepatology 2008; 6:880–889.
28.
•• Patel A, Sayuk GS, Gyawali CP. Acid-based parameters on pH impedance testing predict symptom improvement with medical management better than impedance parameters. Am J Gastroenterol. 2014;109:836–44 Performing pH –impedance testing off PPIs best predicts response to antireflux therapy. Key predictors are acid exposure time and correlation between symptoms and reflux events detected by impedance. CrossRef
29.
•• Francis DO, Goutte M, Slaughter JC, et al. Traditional reflux parameters and not impedance monitoring predict outcomes after fundoplication in extraesophageal reflux. Laryngoscope. 2011;121:1902–9 Based on over 100 patients going to surgery, the best predictions of success was % time pH > 10%, presence of heartburn/regurgitation and large hiatal hernia. Neither symptom correlation or impedance parameters were predictive. CrossRef
30.
Sanagapallis S, Sweis R. Combined pH impedance testing for reflux: current state of play and future challenges. Frontline Gastroenterology. 2017;8:154–5.CrossRef
31.
Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with GERD on and off therapy. Clin Gastroenterol Hepatol. 2009;7:743–8.CrossRef
32.
Frazzon M, Piccoli M, Conigliaro R, et al. Refractory GERD as diagnosed by impedance pH monitoring can be cured by laparoscopic fundoplication. Surg Endosc. 2013;27:2940–6.CrossRef
33.
• Patel A, Wang D, Sainami N, et al. Distal mean nocturnal baseline impedance on pH impedance monitoring predicts reflux burden and symptomatic outcome in GERD. Aliment Pharmacol Ther. 2016;44:890–8 Distal esophageal means nocturnal baseline impedance negatively correlates with acid exposure time. When assessed off PPIs, this measure is independently predictive of symptomatic improvement following anti-reflux therapy. CrossRef
34.
•• Frazzoni M, Savarino E, de Bortoli N, et al. Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease. Clin Gastroenterol Hepatol. 2016;14:–40, 6 Study in 68 esophagitis and 221 NERD patients suggesting high diagnostic yield of nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index.
Metadata
Title
Wireless 24, 48, and 96 Hour or Impedance or Oropharyngeal Prolonged pH Monitoring: Which Test, When, and Why for GERD?
Authors
Soojong Chae
Joel E. Richter
Publication date
01-11-2018
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 11/2018
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-018-0659-0
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits